MicroVue™ FGF-23 ELISA (C-Term)

The MicroVue Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.

Product Specifications

Citations	35
Specimen	Plasma or Cell Culture Supernatent, 200 µL
LLOQ	1.5 RU/mL
ULOQ	N/A
Assay Time	3.5 hours
Cross Reactivity	None

Technical Documents

Ordering Information

For Research Use Only. Not for use in diagnostic procedures.

Catalog Number	60-6100
Catalog Number (CE)
Size	96 wells/test
Price (USD)	$745.00
Price (EURO)	660,00 €

Request an Order

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	contact-us@quidelortho.com
EU Email	contact-emea@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	The MicroVue Human FGF-23 (C-Term) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.
Size	96 wells/test
Form	96 well plate with 12 eight-well strips in a resealable foil pouch
Specimen	Plasma or Cell Culture Supernatent, 200 µL
Limit of Detection (LOD)	1.5 RU/mL
Lower Limit of Quantitation (LLOQ)	1.5 RU/mL
Upper Limit of Quantitation (ULOQ)	N/A
Intra Assay	1.4 - 2.4%
Inter Assay	2.4 - 4.7%
Standards	6
Controls	2
Sample Values	N/A
Assay Time	3.5 hours
Cross Reactivity	None
Storage	Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components
Background	Fibroblast growth factor 23 (FGF-23), which is produced by bone cells, is a novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
FGF-23, Left Ventricular Hypertrophy, and Mortality in Patients With CKD: A Revisit With Mediation Analysis	2024	ELISA	Human	Plasma	Chronic Kidney Disease
Blood concentrations of α-Klotho and FGF-23 exhibit no correlation with bone mineral density in elderly individuals	2024	ELISA	Human	Serum
Prostaglandin E2 signaling through prostaglandin E receptor subtype 2 and Nurr1 induces fibroblast growth factor 23 production	2024	ELISA	Human	Serum
Fibroblast growth factor 23-mediated regulation of osteoporosis: Assessed via Mendelian randomization and in vitro study	2024	ELISA	Human	Serum	Osteoporosis
Associations of Intact and C-Terminal FGF23 with Inflammatory Markers in Older Patients Affected by Advanced Chronic Kidney Disease	2024	ELISA	Human	Plasma	Chronic Kidney Disease
Evaluation of a Method for Fibroblast Growth factor-23: A Novel Biomarker of Adverse Outcomes in Patients With Renal Disease.	2010	ELISA	Human	Plasma
Evaluation of a Method for Fibroblast Growth factor-23: A Novel Biomarker of Adverse Outcomes in Patients With Renal Disease.	2010	ELISA	Human	Serum
Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.	2018	ELISA	Human	Plasma	Diabetes
Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension.	2019	ELISA	Human	Plasma	Hypertension (Children)
Iron Deficiency, Elevated Erythropoietin, Fibroblast Growth Factor 23, and Mortality in the General Population of the Netherlands: A Cohort Study.	2019	ELISA	Human	Plasma
Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.	2020	ELISA	Human	Plasma	Chronic Kidney Disease
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease	2005	ELISA	Human	Serum
Determination of fibroblast growth factor 23	2009	ELISA	Human	Plasma
Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis	2009	ELISA	Human	HEK293 cells
Defective O-glycosylation due to a novel homozygous S129P mutation is associated with lack of fibroblast growth factor 23 secretion and tumoral calcinosis	2009	ELISA	Human	Plasma
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active	2010	ELISA	Human	Plasma
The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease	2010	ELISA	Human	Plasma
Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature	2011	ELISA	Human	Serum
Early skeletal and biochemical alterations in pediatric chronic kidney disease	2012	ELISA	Human	Plasma
Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function	2012	ELISA	Human	Serum
Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients	2012	ELISA	Human	Serum	Chronic Kidney Disease
Intact fibroblast growth factor 23 and fragments in plasma from Gambian children	2013	ELISA	Human	Plasma
Biological variability of plasma intact and C-terminal FGF23 measurements	2012	ELISA	Human	Plasma
Novel SLC34A3 mutation causing hereditary hypophosphataemic rickets with hypercalciuria in a Gambian family	2013	ELISA	Human	Plasma
Associations among total and food additive phosphorus intake and carotid intima-media thickness--a cross-sectional study in a middle-aged population in Southern Finland	2013	ELISA	Human	Plasma
A low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients	2013	ELISA	Human	Serum
Predictors of intact and C-terminal fibroblast growth factor 23 in Gambian children	2013	ELISA	Human	Plasma
The use of fibroblast growth factor 23 testing in patients with kidney disease.	2014	ELISA	Human	Plasma
Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease	2018	ELISA	Human	Plasma	Acute Coronary Syndrome
Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin	2014	ELISA	Human	Plasma
Osteocytic protein expression response to doxercalciferol therapy in pediatric dialysis patients	2015	ELISA	Human	Plasma
Aortic Artery and Cardiac Valve Calcification are Associated with Mortality in Chinese Hemodialysis Patients: A 3.5 Years Follow-up	2015	ELISA	Human	Plasma	MHD
Plasma Levels of Monocyte Chemoattractant Protein-1, n-Terminal Fragment of Brain Natriuretic Peptide and Calcidiol Are Independently Associated with the Complexity of Coronary Artery Disease	2016	ELISA	Human	Plasma	Acute Coronary Syndrome
C-Terminal to Intact Fibroblast Growth Factor 23 Ratio in Relation to Estimated Glomerular Filtration Rate in Elderly Population	2016	ELISA	Human	Plasma
Dietary phosphate supplement does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia	2016	ELISA	Human	Plasma
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy	2016	ELISA	Human	Plasma
Fibroblast Growth Factor 23-Induced Hypophosphatemia in Acute Leukemia.	2018	ELISA	Human	Plasma
Aptamer-Based Proteomics Identifies Mortality-Associated Serum Biomarkers in Dialysis-Dependent AKI Patients	2018	ELISA	Human	Serum
The Heart and Kidney: Abnormal Phosphate Homeostasis Is Associated With Atherosclerosis.	2018	ELISA	Human	Plasma
Tumor-induced osteomalacia: experience from three tertiary care centres In India	2019	ELISA	Human	Serum	Hypoparathyroidism

Certificate of Analysis

Showing results for

No results found for